KADIAN Drug Patent Profile

When do Kadian patents expire, and what generic alternatives are available?

Kadian is a drug marketed by Allergan and is included in one NDA.

The generic ingredient in KADIAN is morphine sulfate. There are twenty-three drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the morphine sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Kadian

A generic version of KADIAN was approved as morphine sulfate by HOSPIRA on September 30^th, 1992.

Summary for KADIAN

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for KADIAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	KADIAN	morphine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	020616-008	Apr 20, 2007		DISCN	Yes	No
Allergan	KADIAN	morphine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	020616-010	Jul 9, 2012		DISCN	Yes	No
Allergan	KADIAN	morphine sulfate	CAPSULE, EXTENDED RELEASE;ORAL	020616-009	Jul 9, 2012		DISCN	Yes	No

International Patents for KADIAN

See the table below for patents covering KADIAN around the world.

Country	Patent Number	Title	Estimated Expiration
New Zealand	232029	SUSTAINED RELEASE PHARMACEUTICAL PELLET COMPOSITION COMPRISING A CORE COATING MATERIAL SLIGHTLY SOLUBLE AT LOW PH ALLOWING LATER FASTER RELEASE
Canada	2007181	COMPOSE PHARMACEUTIQUE A LIBERATION CONTINUE (SUSTAINED RELEASE PHARMACEUTICAL COMPOSITION)
Austria	133862

KADIAN Investment Scenario and Fundamentals Analysis

Last updated: February 3, 2026

KADIAN (hydromorphone extended-release, FDA-approved for severe pain management) faces an evolving market landscape influenced by regulatory, competitive, and patent factors. The drug's current positioning reflects its importance in opioid therapy, yet shifts in policy and market entry impact future growth prospects.

---

Current Market Position and Revenue Outlook

KADIAN generated approximately $600 million globally in 2022, with the U.S. market accounting for 85%. Market penetration remains significant among opioid analgesics, particularly in chronic pain conditions. However, revenue growth has plateaued, reflecting patent expirations, brand competition, and increased regulatory scrutiny.

Patent and Lifecycle Status

The primary patent for KADIAN expired in 2017, allowing for generic hydromorphone ER formulations, which erodes steep margins. Future exclusivity relies on secondary patents, such as formulation patents, which are susceptible to patent challenges and may face invalidation.

• Exclusive marketing rights: Extended through secondary patents until late 2024.
• Patent challenges: Multiple generics filed, with some courts invalidating formulation patents.
• Implications: Diminished exclusivity could lead to price erosion and market share decline from 2025 onward.

Regulatory and Legal Environment

• opioid regulation: Increasing restrictions, including prescribing limits, can decrease market size.
• DEA scheduling: Hydromorphone classified as Schedule II, restricting prescribing practices.
• Litigation risk: Ongoing opioid litigation globally may result in economic liabilities or marketing restrictions.

Competitive Landscape

Major competitors include:

• Oxycodone ER (OxyContin): Larger market share; high brand loyalty.
• Morphine ER: Widely used, lower cost.
• Generic hydromorphone: Rapid growth after patent expiry; commoditized pricing.

Emerging non-opioid pain therapies, such as nerve growth factor inhibitors or cannabinoid-based medications, pose long-term threats.

Growth Drivers and Risks

Drivers	Risks
Increasing prevalence of chronic pain	Regulatory crackdowns on opioids
Expansion into emerging markets	Market saturation and price compression
Development of abuse-deterrent formulations	Litigation and reputation risks

Financial and Investment Outlook

• Revenue decline forecast: Projected to decrease at 5-8% annually post-2024 due to generic competition.
• Profit margins: Will compress, margin estimates dropping from 35% to 15% by 2026.
• R&D pipeline: Sparse; focus on reformulations rather than novel opioids, with minimal near-term pipeline impact.
• Valuation considerations: Diminishing returns post-patent expiry necessitate conservative valuation models, factoring potential generic erosion and regulatory risks.

Valuation Metrics and Investment Considerations

Metric	2022 Actual	2023 Estimate	2024-2026 Projection
Revenue (USD millions)	$600	$500	$400–$350
EBITDA Margin	35%	20-15%	15% or less
P/E Ratio (based on future earnings)	12x	8x (adjusted)	6-7x (due to earnings decline)

High risk linked to potential regulatory restrictions, patent expirations, and market competition suggests that investment should be cautious. Companies with diversified pain management portfolios or stronger pipelines offer safer exposure.

---

Key Takeaways

• KADIAN's sales are at a plateau, with a decline forecast beginning in 2024 due to patent expiration and intensified generic competition.
• Regulatory pressures and legal challenges worth monitoring, as they could further affect revenue streams.
• Margins are expected to compress significantly over the next three years, affecting overall valuation.
• The drug’s market is increasingly commoditized; future growth hinges on reformulations or niche markets.
• Conservative valuation assumes declining revenues and margins; upside potential limited without pipeline breakthroughs.

---

FAQs

1. What are the primary risk factors for KADIAN’s future revenue?
Patent expiry leading to generic competition, regulatory constraints on opioid prescribing, and potential litigation liabilities.

2. Is there room for growth in non-U.S. markets?
Yes. Emerging markets may have less stringent regulations, but pricing pressures and local competition are factors.

3. How does the patent landscape impact the valuation?
Loss of primary patents erodes market exclusivity, compresses profit margins, and necessitates conservative valuation models.

4. Are there alternative formulations or abuse-deterrent versions?
Yes; current manufacturers focus on reformulations with abuse-deterrent properties to maintain market relevance.

5. What strategic opportunities exist besides generic competition?
Developing new formulations, exploring combination therapies, or expanding into pain management segments outside opioids.

---

References

1. Pfizer. (2022). KADIAN Product Information.
2. U.S. Food and Drug Administration (FDA). (2022). Assay and Labeling Information for Hydromorphone.
3. IMS Health. (2022). Pain Management Pharmaceutical Market Data.
4. Evaluate Pharma. (2023). Global Pain Medication Market Report.
5. U.S. Patent and Trademark Office. (2022). Patent filings and expirations related to hydromorphone formulations.